Novo Nordisk A/S (NYSE:NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro.Novo Nordisk’s stock was significantly hit when the company shared headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program, investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.First in May, Novo Nordisk lowered its 2025 sales growth, then again in July, it further trimmed its 2025 guidance. Dur ...

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.Eli Lilly (LLY +3.44%) is executing very well right now, and Wall Street is aware of that. The stock's price-to-earnings (P/E) ratio of 50 is below its five-year average of 54, but very high on an absolute basis. For reference, the S&P 500 index has a P/E ratio of 28.5. Before you buy shares in Lilly, think about what might happen over the next decade.Why is Eli Lilly doing so well right now?The big story around Eli Lilly is ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. Eli Lilly's Mounjaro Added to China's National Health Insurance for Diabetes Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and othe ...

Eli Lilly shares have climbed in the double digits this year.Generally, investors turn to pharmaceutical stocks to add an element of safety to their portfolios. These stocks aren't known for rapid growth, but instead, for steady growth that you can count on over time -- this reliability is due to the fact that patients need their medicines, and that supports drugmakers' revenue through any economic environment.But in recent years, one pharma stock in particular has been behaving like a growth stock -- in fa ...

The company's worst days might be behind it.The past 18 months have been absolutely terrible for Novo Nordisk (NVO 0.22%). The Denmark-based drugmaker has faced poor financial results and clinical setbacks, all of which have driven its stock price down. Its stock price is barely hovering above multiyear lows at the moment. The pharmaceutical giant recognizes there is an issue, and management has made some moves to attempt a comeback.Can Novo Nordisk get its comeback going in 2026? Let's discuss two things t ...

BREAKING: Stock Market Strong Outside AI Sector Today's Spotlight Advanced Buying Strategies Workshop Purchase IBD's pre-recorded Advanced Buying Strategies workshop for only $395. Get Market Insights on IBD Live Pharma companies, airlines, mining companies, and retailers all benefited from the rotation out of tech that happened over the course of last week. Household names like Eli Lilly, Urban Outfitters, and United Airlines lead this diversified set of companies showing strength outside of the tech indus ...

Key Takeaways Shares are down 41.5% YTD in 2025 despite U.S. supply constraints for Ozempic and Wegovy easing.2025 guidance cuts blamed intensifying LLY competition, FX hits, and broad use of compounded semaglutide.Novo Nordisk announced restructuring and a U.S. pricing deal as margin and execution risks mount.Novo Nordisk (NVO) has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type ...

Key Takeaways Hims & Hers is extending its comprehensive Weight Loss Program to customers across the United Kingdom.The move follows U.S. success and supports broader international growth, including launches in Canada.The U.K. rollout offers seamless access to personalized programs, GLP-1 options, and 24/7 support.Hims & Hers (HIMS) recently announced that it is expanding access to its comprehensive Weight Loss Program to customers in the United Kingdom. The company is launching its Hers platform to provide ...

核心观点 - 礼来公司新一代减肥药Retatrutide在3期临床试验中展现出创纪录的减重疗效，平均减重达28.7%，显著超越现有主流药物，并显示出缓解膝骨关节炎疼痛的潜力，有望为公司开辟新的重磅产品线 [1][3] 临床试验结果 - 针对肥胖合并膝骨关节炎患者的3期临床试验显示，接受最高剂量Retatrutide治疗68周后，患者平均体重下降28.7%，约合71.2磅 [1][4] - 该减重效果显著高于礼来已上市药物Zepbound（约22.5%）和竞争对手诺和诺德的Wegovy（低于20%） [1] - 药物通过模拟三种肠道激素调节食欲并可能增加能量消耗，作用机制比现有药物更复杂 [3] 市场反应与公司前景 - 积极的试验数据公布后，礼来公司股价在盘前交易中上涨1.2%，隔夜收涨1.6% [1] - 分析认为Retatrutide的成功可能延续公司由Mounjaro和Zepbound等药物带来的爆炸性增长，开辟新的重磅产品线 [1] - 公司预计关于该药物的另外七项3期临床试验将在2026年完成 [3] 药物特性与潜在应用 - 除了显著减重，研究还发现药物能有效缓解患者的膝盖疼痛，为其未来的应用场景和市场定位提供了更多想象空间 [3] - 公司高管表示，该药可能成为有显著减重需求和特定并发症（包括膝骨关节炎）患者的重要选择 [3] - 试验招募对象为未患糖尿病但身体质量指数至少为35的重度肥胖症及膝骨关节炎患者 [4] 副作用与目标人群 - 研究发现药物伴随恶心、腹泻等肠道副作用，这与同类减肥药物的已知情况类似 [5] - 分析师指出，Retatrutide的副作用发生率高于Wegovy和Zepbound等较早药物，但总体上仍符合该类药物的特征 [5] - 部分受试者因体重下降过多而中止治疗，分析师认为该药物的目标人群将是BMI指数非常高的患者 [5]

Key Takeaways LLY relies on its expanding obesity pipeline as more biotech challengers enter the market.GPCR's aleniglipron showed notable weight-loss data, adding pressure in the obesity space.LLY pushes orforglipron and retatrutide toward late-stage milestones to preserve obesity momentum.Eli Lilly and Company (LLY) is one of the two companies that dominate the booming cardiometabolic space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the ...